Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

November 21, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
November 14, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 7, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
November 2, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
October 26, 2023

Immunic to Participate in Scientific and Industry Conferences in November
October 16, 2023

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
October 15, 2023

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
October 11, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
October 9, 2023

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
October 4, 2023

Immunic to Participate in Scientific Conferences in October
September 6, 2023

Immunic to Participate in Industry and Investor Conferences in September
August 17, 2023

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 3, 2023

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 1, 2023

Immunic to Participate in Investor and Scientific Conferences in August
July 27, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023

Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023

Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
May 6, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
May 4, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
April 27, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
April 26, 2023

Immunic to Participate in Investor and Scientific Conferences in May
April 5, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Show per page